Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG004 in Acute Spinal Cord Injury
NCT06817577Phase 1Active, not recruiting
- Sponsor
- NovaGo Therapeutics
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NG004 in spinal cord injury (SCI), sponsored by NovaGo Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
NG004
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06817577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817577.